Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd Ads (NQ: BGNE )

311.97 USD -2.03 (-0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 304,122
Open 321.09
Bid (Size) 281.00 (1)
Ask (Size) 311.98 (1)
Prev. Close 314.00
Today's Range 309.52 - 327.39
52wk Range 155.16 - 388.97
Shares Outstanding 1,197,609,020
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its PARP inhibitor pamiparib has... 
From Business Wire News Releases
BeiGene Reports First Quarter 2021 Financial Results
BeiGene reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021. 
From Business Wire News Releases

Performance

YTD
+19.52%
+19.52%
1 Month
+1.20%
+1.20%
3 Month
-15.47%
-15.47%
6 Month
+11.42%
+11.42%
1 Year
+91.09%
+91.09%

More News

Read More
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against
From Business Wire News Releases
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
From Business Wire News Releases
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
From Business Wire News Releases
BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies
Tags Health Care JNJ General
From Benzinga
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
From Business Wire News Releases
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
Tags Market News Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
From Business Wire News Releases
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China
From Business Wire News Releases
QQQJ's Underlying Holdings Imply 11% Gain Potential
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.